How I Lost 25 Pounds in 2.5 Months

Losing 25 pounds in 2.5 months might sound extreme, but my journey was the opposite of harsh or restrictive. I didn’t starve myself or live in the gym. My approach used two breakthrough peptie Retatrutide and Human Growth Hormone (HGH) which supported natural fat loss, muscle preservation, and overall metabolic health.

What Made This Approach Different

During menopause, my weight fluctuated constantly, and my body began changing in ways I didn’t anticipate. I could no longer perform like the athlete I had been up until around age 52, and that was a tough reality to face. Even though I’d always carried a bit of belly fat, there were days when I looked several months pregnant; bloated, uncomfortable, and frustrated with my reflection. The physical changes came hand in hand with intense mood swings and emotional ups and downs… but that’s a story for another blog.

When a friend introduced me to Retatrutide, I was skeptical at first. I’d heard plenty of negative stories on TV about side effects, lawsuits, and disappointing results. Still, I wanted something that worked, that was sustainable and free of harsh side effects. Despite my hesitation, I decided to try it, realizing I had little to lose after years of struggling with traditional diet plans and exercise routines that I rarely managed to stick with.

My new approach focused on balance, not burnout, and my activity level became simple but consistent: plenty of walking and a bit of cardio.Retatrutide and HGH made that balance possible by addressing the real root causes of my stubborn weight that I beleive was a hormonal imbalance and insulin resistance. For the first time, I felt relief from the shame of late-night sugar cravings and the constant guilt of not being able to “just stop eating chocolate.” Letting go of calorie counting was mentality freeing. Truthfully, I’d never managed to follow that approach anyway, despite all my self-talk that I would.

What Is Retatrutide?

Retatrutide is an investigational drug developed as a triple agonist that activates GLP-1, GIP, and glucagon receptors. These receptors regulate appetite, glucose metabolism, and energy expenditure (Lilly, 2023).

In clinical trials, participants receiving Retatrutide achieved up to 24% body weight reduction over 48 weeks, with improvements in blood sugar, blood pressure, and cholesterol (Jastreboff et al., 2023). Unlike older GLP-1 medications, Retatrutide helps preserve lean muscle mass while promoting fat oxidation, which supports a stronger, healthier body composition.

In my own experience, Retatrutide helped stabilize appetite, reduce cravings, and sustain energy levels throughout the day. It didn’t feel like “dieting”, it felt like my metabolism finally worked the way it should.

How Human Growth Hormone (HGH) Complements Retatrutide

While Retatrutide handled the metabolic side, Human Growth Hormone (HGH) supported recovery, body composition, and cellular repair. HGH naturally declines with age, but medically supervised replacement in adults with clinical deficiency can improve energy, fat metabolism, and sleep quality (Mayo Clinic, 2022).

When integrated, HGH can:

  • Enhance lean muscle maintenance and recovery
  • Improve sleep and mental clarity
  • Support skin and connective tissue health

In my case, combining HGH with Retatrutide helped my body recover faster, maintain muscle tone, and feel rejuvenated overall.

Find a certified provider of Retatrutide and HGH

My 10-Week Results

After ten weeks:

  • I lost 25 pounds of body fat.
  • My blood pressure, cholesterol, and glucose levels improved significantly.
  • My sleep quality and mood improved dramatically.
  • I felt stronger, more confident, and genuinely healthy.

This wasn’t a crash diet or a short-term fix and it is based on scientce rather that diet culture and aligned with my lifestyle, and for me that is very importnt.

Suggested Internal Links

References

Eli Lilly and Company. (2023). Retatrutide: A triple agonist targeting GLP-1, GIP, and glucagon receptors. Retrieved from https://investor.lilly.com/news-releases

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., & Kwon, S. (2023). Triple-hormone receptor agonist retatrutide in individuals with obesity: A randomized, double-blind, phase 2 trial. The New England Journal of Medicine, 389(1), 12–24. https://doi.org/10.1056/NEJMoa2303303

Mayo Clinic. (2022). Human Growth Hormone (HGH): Uses and side effects. Retrieved from https://www.mayoclinic.org/healthy-lifestyle/healthy-aging/in-depth/growth-hormone/art-20045735

Comments (0)